Global Brain Aneurysm Market Insights, Forecast to 2025

2 Global Brain Aneurysm Quarterly Market Size Analysis

• 2.1 Brain Aneurysm Business Impact Assessment - COVID-19
  • 2.1.1 Global Brain Aneurysm Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
• 2.2 Global Brain Aneurysm Quarterly Market Size 2020-2021
• 2.3 COVID-19-Driven Market Dynamics and Factor Analysis
  • 2.3.1 Drivers
  • 2.3.2 Restraints
  • 2.3.3 Opportunities
  • 2.3.4 Challenges

3 Quarterly Competitive Assessment, 2020

• 3.1 By Players, Global Brain Aneurysm Quarterly Market Size, 2019 VS 2020
• 3.2 By Players, Brain Aneurysm Headquarters and Area Served
• 3.3 Date of Key Players Enter into Brain Aneurysm Market
• 3.4 Key Players Brain Aneurysm Product Offered
• 3.5 Mergers & Acquisitions, Expansion Plans

4 Impact of Covid-19 on Brain Aneurysm Segments, By Type

• 4.1 Introduction
  • 1.4.1 Surgical clipping
  • 1.4.2 Endovascular coiling
  • 1.4.3 Flow diverter
  • 1.4.4 Other
• 4.2 By Type, Global Brain Aneurysm Market Size, 2019-2021

5 Impact of Covid-19 on Brain Aneurysm Segments, By Application

• 5.1 Overview
  • 5.5.1 Hospital
  • 5.5.2 Clinics
  • 5.5.3 Other
• 5.2 By Application, Global Brain Aneurysm Market Size, 2019-2021
  • 5.2.1 By Application, Global Brain Aneurysm Market Size by Application, 2019-2021

6 Geographic Analysis

• 6.1 Introduction
• 6.2 North America
  • 6.2.1 Macroeconomic Indicators of US
  • 6.2.2 US
  • 6.2.3 Canada
• 6.3 Europe
  • 6.3.1 Macroeconomic Indicators of Europe
  • 6.3.2 Germany
  • 6.3.3 France
  • 6.3.4 UK
  • 6.3.5 Italy
• 6.4 Asia-Pacific
  • 6.4.1 Macroeconomic Indicators of Asia-Pacific
  • 6.4.2 China
  • 6.4.3 Japan
  • 6.4.4 South Korea
  • 6.4.5 India
  • 6.4.6 ASEAN
• 6.5 Rest of World
  • 6.5.1 Latin America
  • 6.5.2 Middle East and Africa

7 Company Profiles

• 7.1 Medtronic
  • 7.1.1 Medtronic Business Overview
  • 7.1.2 Medtronic Brain Aneurysm Quarterly Revenue, 2020
  • 7.1.3 Medtronic Brain Aneurysm Product Introduction
  • 7.1.4 Medtronic Response to COVID-19 and Related Developments
• 7.2 Codman & Shurtleff
  • 7.2.1 Codman & Shurtleff Business Overview
  • 7.2.2 Codman & Shurtleff Brain Aneurysm Quarterly Revenue, 2020
  • 7.2.3 Codman & Shurtleff Brain Aneurysm Product Introduction
  • 7.2.4 Codman & Shurtleff Response to COVID-19 and Related Developments
• 7.3 Raumedic
  • 7.3.1 Raumedic Business Overview
  • 7.3.2 Raumedic Brain Aneurysm Quarterly Revenue, 2020
  • 7.3.3 Raumedic Brain Aneurysm Product Introduction
  • 7.3.4 Raumedic Response to COVID-19 and Related Developments
• 7.4 Vittamed
  • 7.4.1 Vittamed Business Overview
  • 7.4.2 Vittamed Brain Aneurysm Quarterly Revenue, 2020
  • 7.4.3 Vittamed Brain Aneurysm Product Introduction
  • 7.4.4 Vittamed Response to COVID-19 and Related Developments
• 7.5 Sophysa
  • 7.5.1 Sophysa Business Overview
  • 7.5.2 Sophysa Brain Aneurysm Quarterly Revenue, 2020
  • 7.5.3 Sophysa Brain Aneurysm Product Introduction
  • 7.5.4 Sophysa Response to COVID-19 and Related Developments
• 7.6 MicroPort Scientific
  • 7.6.1 MicroPort Scientific Business Overview
  • 7.6.2 MicroPort Scientific Brain Aneurysm Quarterly Revenue, 2020
  • 7.6.3 MicroPort Scientific Brain Aneurysm Product Introduction
  • 7.6.4 MicroPort Scientific Response to COVID-19 and Related Developments
• 7.7 Orsan Medical
  • 7.7.1 Orsan Medical Business Overview
  • 7.7.2 Orsan Medical Brain Aneurysm Quarterly Revenue, 2020
  • 7.7.3 Orsan Medical Brain Aneurysm Product Introduction
  • 7.7.4 Orsan Medical Response to COVID-19 and Related Developments
• 7.8 Spiegelberg
  • 7.8.1 Spiegelberg Business Overview
  • 7.8.2 Spiegelberg Brain Aneurysm Quarterly Revenue, 2020
  • 7.8.3 Spiegelberg Brain Aneurysm Product Introduction
  • 7.8.4 Spiegelberg Response to COVID-19 and Related Developments
• 7.9 Johnson & Johnson
  • 7.9.1 Johnson & Johnson Business Overview
  • 7.9.2 Johnson & Johnson Brain Aneurysm Quarterly Revenue, 2020
  • 7.9.3 Johnson & Johnson Brain Aneurysm Product Introduction
  • 7.9.4 Johnson & Johnson Response to COVID-19 and Related Developments
• 7.10 Sophysa
  • 7.10.1 Sophysa Business Overview
  • 7.10.2 Sophysa Brain Aneurysm Quarterly Revenue, 2020
  • 7.10.3 Sophysa Brain Aneurysm Product Introduction
  • 7.10.4 Sophysa Response to COVID-19 and Related Developments
• 7.11 HaiWeiKang
  • 7.11.1 HaiWeiKang Business Overview
  • 7.11.2 HaiWeiKang Brain Aneurysm Quarterly Revenue, 2020
  • 7.11.3 HaiWeiKang Brain Aneurysm Product Introduction
  • 7.11.4 HaiWeiKang Response to COVID-19 and Related Developments
• 7.12 Head Sense Medical
  • 7.12.1 Head Sense Medical Business Overview
  • 7.12.2 Head Sense Medical Brain Aneurysm Quarterly Revenue, 2020
  • 7.12.3 Head Sense Medical Brain Aneurysm Product Introduction
  • 7.12.4 Head Sense Medical Response to COVID-19 and Related Developments
• 7.13 InfraScan
  • 7.13.1 InfraScan Business Overview
  • 7.13.2 InfraScan Brain Aneurysm Quarterly Revenue, 2020
  • 7.13.3 InfraScan Brain Aneurysm Product Introduction
  • 7.13.4 InfraScan Response to COVID-19 and Related Developments
• 7.14 Integra Life Sciences
  • 7.14.1 Integra Life Sciences Business Overview
  • 7.14.2 Integra Life Sciences Brain Aneurysm Quarterly Revenue, 2020
  • 7.14.3 Integra Life Sciences Brain Aneurysm Product Introduction
  • 7.14.4 Integra Life Sciences Response to COVID-19 and Related Developments

8 Key Findings

9 Appendix

• 9.1 About US